• 1. Immobilization of a Zn4 complex on functionalized layered HUS-7: synthesis, structural investigation and catalytic activity
  Divya Jadav,Pooja Shukla,Rajib Bandyopadhyay,Plaban Jyoti Sarma,Ramesh Chandra Deka,Rajesh Kumar,Sourav Das,Nao Tsunoji,Mahuya Bandyopadhyay New J. Chem. 2022 46 9418

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Oxazinanes Morpholines

Research Brief on 1-(morpholin-4-yl)propan-2-ol (CAS: 2109-66-2) in Chemical Biology and Pharmaceutical Applications

1-(morpholin-4-yl)propan-2-ol (CAS: 2109-66-2) is a morpholine derivative that has garnered significant attention in recent years due to its versatile applications in chemical biology and pharmaceutical research. This compound serves as a key intermediate in the synthesis of various bioactive molecules, including kinase inhibitors, antimicrobial agents, and central nervous system (CNS) therapeutics. Its unique structural features, combining a morpholine ring with a hydroxyl-bearing propyl chain, make it a valuable scaffold for drug design and optimization.

Recent studies have highlighted the role of 1-(morpholin-4-yl)propan-2-ol in the development of novel kinase inhibitors, particularly those targeting the PI3K/AKT/mTOR pathway, which is implicated in cancer progression. Researchers have utilized this compound to synthesize derivatives with enhanced selectivity and potency against specific kinase isoforms. For instance, a 2023 study published in the Journal of Medicinal Chemistry demonstrated that modifications to the hydroxyl group of 1-(morpholin-4-yl)propan-2-ol could significantly improve the pharmacokinetic properties of resulting inhibitors, leading to better in vivo efficacy in xenograft models.

In addition to its applications in oncology, 1-(morpholin-4-yl)propan-2-ol has shown promise in the development of antimicrobial agents. A 2022 study in Bioorganic & Medicinal Chemistry Letters reported that derivatives of this compound exhibited potent activity against drug-resistant bacterial strains, including methicillin-resistant Staphylococcus aureus (MRSA). The morpholine moiety was found to enhance membrane permeability, while the hydroxyl group facilitated interactions with bacterial target proteins, providing a dual mechanism of action.

The compound's potential in CNS drug discovery has also been explored. Research published in ACS Chemical Neuroscience in 2023 revealed that 1-(morpholin-4-yl)propan-2-ol derivatives could modulate neurotransmitter systems, particularly those involving dopamine and serotonin receptors. These findings suggest potential applications in treating neurological disorders such as Parkinson's disease and depression. The compound's ability to cross the blood-brain barrier, attributed to its balanced lipophilicity and hydrogen-bonding capacity, makes it an attractive candidate for CNS-targeted therapies.

Synthetic methodologies for 1-(morpholin-4-yl)propan-2-ol have advanced significantly in recent years. Green chemistry approaches, including catalytic hydrogenation and microwave-assisted synthesis, have been developed to improve yield and reduce environmental impact. A 2023 paper in Organic Process Research & Development described a continuous-flow synthesis method that achieved >90% yield with minimal waste generation, addressing scalability challenges for industrial production.

Despite these advancements, challenges remain in the optimization of 1-(morpholin-4-yl)propan-2-ol-based therapeutics. Issues such as metabolic stability, off-target effects, and formulation compatibility require further investigation. Ongoing research is focusing on structure-activity relationship (SAR) studies to identify optimal substitutions on both the morpholine ring and the propanol chain. Computational chemistry and AI-driven drug design approaches are being increasingly employed to accelerate this optimization process.

In conclusion, 1-(morpholin-4-yl)propan-2-ol (CAS: 2109-66-2) represents a versatile and promising scaffold in pharmaceutical research, with applications spanning multiple therapeutic areas. Recent advancements in synthetic chemistry and biological evaluation have expanded its potential, though further research is needed to fully realize its clinical applications. The compound's unique structural features and demonstrated biological activities make it a valuable focus for continued investigation in chemical biology and drug discovery.

• 70289-40-6(morpholine, 2,6-dimethyl-4-propyl-,)
• 7250-87-5(1,3-dimorpholin-4-ylpropan-2-ol)
• 111681-72-2(Morpholine,4-[2-[1-methyl-2-(4-morpholinyl)ethoxy]ethyl]-)
• 452105-36-1((αS)-α-(Aminomethyl)-4-morpholineethanol)
• 73813-49-7(2-(2,6-dimethylmorpholin-4-yl)ethanol)
• 452105-38-3((2R)-1-amino-3-(morpholin-4-yl)propan-2-ol)
• 135913-02-9(6-Bromo-4,4-Dimethylthiochroman)
• 103251-80-5(Morpholine,4,4'-(oxydi-2,1-ethanediyl)bis[2,6-dimethyl-)
• 39849-45-1(1-amino-3-(morpholin-4-yl)propan-2-ol)
• 63295-51-2(4-Morpholineethanol, a,2,6-trimethyl-)